Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013:9:535-49.
doi: 10.2147/VHRM.S44568. Epub 2013 Sep 27.

Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

Affiliations
Randomized Controlled Trial

Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial

G D Radchenko et al. Vasc Health Risk Manag. 2013.

Abstract

Background: The aim of this study was to compare the antihypertensive efficacy of losartan 100 mg + hydrochlorothiazide (HCTZ) 25 mg versus bisoprolol 10 mg + HCTZ 25 mg and their influence on arterial stiffness and central blood pressure (BP).

Methods: Of 60 patients with a mean BP of 173.3 ± 1.7/98.4 ± 1.2 mmHg, 59 were randomized to losartan + HCTZ (n = 32) or bisoprolol + HCTZ (n = 27). Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months. Body mass index, office and 24-hour ambulatory BP, pulse wave velocity (carotid-femoral [PWVE] and radial [PWVM]), noninvasive central systolic BP, augmentation index (AIx), laboratory investigations, and electrocardiography were done at baseline and after 6 months of treatment.

Results: Losartan + HCTZ was as effective as bisoprolol + HCTZ, with target office BP achieved in 96.9% and 92.6% of patients and target 24-hour BP in 75% and 66.7% of patients, respectively, after 6 months. Effective treatment of BP led to significant lowering of central systolic BP, but this was decreased to a significantly (P < 0.05) greater extent by losartan + HCTZ (-23.0 ± 2.3 mmHg) than by bisoprolol + HCTZ (-15.4 ± 2.9 mmHg) despite equal lowering of brachial BP. Factors correlated with central systolic BP and its lowering differed between the treatment groups. Losartan + HCTZ did not alter arterial stiffness patterns significantly, but bisoprolol + HCTZ significantly increased AIx. We noted differences in ΔPWVE, ΔPWVM, and ΔAIx between the groups in favor of losartan + HCTZ. Decreased heart rate was associated with higher central systolic BP and AIx in the bisoprolol + HCTZ group, but was not associated with increased AIx in the losartan + HCTZ group.

Conclusion: Although both treatments decreased both office and 24-hour BP, losartan + HCTZ significantly decreased central systolic BP and had a more positive influence on pulse wave velocity, with a less negative effect of decreased heart rate on AIx and central systolic BP.

Keywords: arterial hypertension; arterial stiffness; central blood pressure; combination therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment scheme. Abbreviations: AH, arterial hypertension; BP, blood pressure; HCTZ, hydrochlorothiazide.
Figure 2
Figure 2
Changes in 24-hour SBP, DBP, and HR on treatment. Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure; HCTZ, hydrochlorothiazide; HR, heart rate.
Figure 3
Figure 3
Changes in arterial stiffness patterns (Δ) in treatment groups. Abbreviations: PWVE, carotid-femoral pulse wave velocity; PWVM, radial pulse wave velocity; Alx, augmentation index.
Figure 4
Figure 4
Changes in central systolic blood pressure in treatment groups. Note: *Statistically significant versus baseline. Abbreviation: HCTZ, hydrochlorothiazide.

References

    1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. - PubMed
    1. Gil-Extremera B. ABPM study: efficacy of two fixed dose combinations, enalapril/nitrendipine versus. losartan/hydrochlorothiazide, in not controlled mild-moderate hypertensive patients. Am J Hypertens. 2003;16:A116.
    1. Wilson TW, Lacourcière Y, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ. 1998;159:469–476. - PMC - PubMed
    1. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003. - PubMed
    1. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. J Am Coll Cardiol. 2008;52:1062–1072. - PubMed

Publication types

MeSH terms